Oncotarget

Research Papers:

miR-145 promotes osteosarcoma growth by reducing expression of the transcription factor friend leukemia virus integration 1

Panfeng Wu, Jieyu Liang, Fang Yu, Zhengbing Zhou, Juyu Tang and Kanghua Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:42241-42251. https://doi.org/10.18632/oncotarget.9948

Metrics: PDF 753 views  |   HTML 1192 views  |   ?  


Abstract

Panfeng Wu1, Jieyu Liang1, Fang Yu1, Zhengbing Zhou1, Juyu Tang1, Kanghua Li1

1Department of Orthopedics, Xiang Ya Hospital Central South University, Changsha, Hunan, People's Republic of China

Correspondence to:

Kanghua Li, email: adeleyd@163.com

Juyu Tang, email: tangjuyu7749@163.com

Keywords: miR-145, FLI-1, osteosarcoma

Received: September 21, 2015     Accepted: May 20, 2016     Published: June 11, 2016

ABSTRACT

Osteosarcoma (OS) is the most common malignant bone tumor in children and young adults. miR-145 is a microRNA highly expressed in vascularized tissues and has been widely studied in cancers. In this study, we explored the expression and function of miR-145 in OS. We found that miR-145 was consistently under-expressed in OS tissues and cell lines as compared to normal bone tissues and osteoblast cells. Ectopic expression of miR-145 in OS cells inhibited their proliferation and migration and induced apoptosis. miR-145 targets a putative microRNA regulatory element (MRE) in the 3′-UTR of friend leukemia virus integration 1 gene (FLI-1), and its abundance was inversely related to FLI-1 expression in OS tissues and cell lines. miR-145 decreased expression FLI-1 protein and mRNA, but mutation of the miR-145 MRE sequence in the FLI-1 3′-UTR abolished the activity of miR-145 in a reporter assay. Restored expression of FLI-1 diminished miR-145-mediated suppression of tumor progression. These results suggest that miR-145 acts as a tumor suppressor by directly reducing expression of FLI-1, and that the miR-145/FLI-1 pathway is important for tumor progression in OS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9948